Stockreport

Could ORIC Pharmaceuticals' (ORIC) Pipeline Progress Reveal the Company's Edge in Cancer Therapeutics? [Yahoo! Finance]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF of enozertinib, an investigational, brain-penetrant EGFR inhibitor for non-small cell lung cancer, and presented new preclinical data for ORIC-944 in prostate cancer at [Read more]